Cargando…

Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients

PURPOSE: This study aimed to determine the oncologic efficacy of gonadotropin-releasing hormone (GnRH) agonist treatment concurrent with chemotherapy in a neoadjuvant setting. METHODS: A retrospective analysis was performed on 332 cases of invasive breast cancer in patients who were <40 years old...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hee Jeong, Yoon, Tae-In, Chae, Hee Dong, Kim, Jeong Eun, Chae, Eun Young, Yu, Jong Han, Sohn, Guiyun, Ko, Beom Seok, Lee, Jong Won, Son, Byung Ho, Ahn, Sei Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705088/ https://www.ncbi.nlm.nih.gov/pubmed/26770243 http://dx.doi.org/10.4048/jbc.2015.18.4.365

Ejemplares similares

Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
por: Sohn, Guiyun, et al.
Publicado: (2016)

Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
por: Choi, Hee Jun, et al.
Publicado: (2023)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy
por: Chun, Jung Whan, et al.
Publicado: (2021)

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Gwark, Sungchan, et al.
Publicado: (2021)

Factors Predicting Locoregional Recurrence After Neoadjuvant Chemotherapy and Nipple-Sparing/Skin-Sparing Mastectomy With Immediate Breast Reconstruction
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Non-sentinel node metastasis prediction during surgery in breast cancer patients with one to three positive sentinel node(s) following neoadjuvant chemotherapy
por: Chun, Jung Whan, et al.
Publicado: (2023)

MRI-based 3D-printed surgical guides for breast cancer patients who received neoadjuvant chemotherapy
por: Ko, Beom Seok, et al.
Publicado: (2019)

A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2015)

Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients
por: Gwark, Sungchan, et al.
Publicado: (2020)

Impact of Immunohistochemistry-Based Molecular Subtype on Chemosensitivity and Survival in Patients with Breast Cancer Following Neoadjuvant Chemotherapy
por: Yoo, Changhoon, et al.
Publicado: (2012)

Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer
por: Lee, Young-Won, et al.
Publicado: (2023)

Publisher Correction: Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients
por: Gwark, Sungchan, et al.
Publicado: (2021)

Daily Collection of Self-Reporting Sleep Disturbance Data via a Smartphone App in Breast Cancer Patients Receiving Chemotherapy: A Feasibility Study
por: Min, Yul Ha, et al.
Publicado: (2014)

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
por: Lambertini, Matteo, et al.
Publicado: (2019)

A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer
por: Lee, Sae Byul, et al.
Publicado: (2018)

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
por: Kim, Hee Jeong, et al.
Publicado: (2020)

Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis
por: Shen, Yan-Wei, et al.
Publicado: (2015)

Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Lee, Hee Jin, et al.
Publicado: (2013)

Survival Outcomes of Different Treatment Methods for the Ipsilateral Breast of Occult Breast Cancer Patients with Axillary Lymph Node Metastasis: A Single Center Experience
por: Woo, Sang Min, et al.
Publicado: (2013)

Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor?Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
por: Suh, Koung Jin, et al.
Publicado: (2017)

Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma
por: Yoon, Tae In, et al.
Publicado: (2023)

Usefulness of 3D-surgical guides in breast conserving surgery after neoadjuvant treatment
por: Lee, Han Shin, et al.
Publicado: (2021)

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Improved Model for Predicting Axillary Response to Neoadjuvant Chemotherapy in Patients with Clinically Node-Positive Breast Cancer
por: Kim, Hyung Suk, et al.
Publicado: (2017)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study
por: Lee, Sae Byul, et al.
Publicado: (2018)

SAT-304 Unexplained Asymptomatic Hyperestrogenism in Central Precocious Puberty Patient Treated with Gonadotropin Releasing Hormone Agonist
por: Kim, Dae Hyun, et al.
Publicado: (2019)

Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer
por: Kim, Hyung Suk, et al.
Publicado: (2019)

Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
por: Kim, Hee Jeong, et al.
Publicado: (2015)

Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
por: Lee, Sae Byul, et al.
Publicado: (2021)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study
por: Woo, Joohyun, et al.
Publicado: (2021)

Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer
por: Lim, Sung Hee, et al.
Publicado: (2021)

Posterior reversible encephalopathy syndrome in a woman who used gonadotropin-releasing hormone agonists: a case report
por: Lee, Minhee, et al.
Publicado: (2019)

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer
por: Lee, Sae Byul, et al.
Publicado: (2019)

The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies
por: Park, Chan-Yong, et al.
Publicado: (2014)

Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
por: Ha, Joo Young, et al.
Publicado: (2021)

The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty
por: Kim, Sung Woo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qs6e0fivk9ji9cc1udncdt17cq